CFO states line of credit is available from Al but the company is exploring other alternatives so they may not need it. What does this tell you? Would they dare dillute again when they have a source of funding from Al/
Does anybody else wonder if Al is blowing smoke up our skirts? For example, how could physicians in these "blind" trials make definitive statements about this drug's effectiveness. Are they blind or are we blind? (I guess this adds a new connotation to the term "double-blind!")
The company stated they have enough cash on hand to carry them through the summer when Phase III results will be announced. At that point they said if needed they have Alfred Mann's credit line which was just reinstated available to for use, but a more like alternative funding would come from outstanding warrants that could be exercised and bring in about $90 million in new cash. They believe positive Phase III results could be the trigger that pushes the owners of these warrants to exercise them. I don't see any new offerings that would dilute shareholder value.